← All themes
Theme

Oncology

Every analyzed stock in Oncology — 290 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Oncology risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
41 /100 Elevated ▼ -6 mild
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
61 /100 High ▼ -5 mild
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 55 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
35 Moderate
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 55 stocks.
39 Moderate
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
51 Elevated
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
51.6%
Elevated
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
58%
Elevated
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
31%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 238 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Oncology
Oncology — Sep 7 – Sep 11, 2026 (Wk 37): Oncology Theme: Earnings, Analyst Targets, and Pipeline Updates Drive Activity →
This week in oncology saw a mix of company-specific news, including earnings reports and analyst target adjustments, alongside updates on drug pipelines. These developments highlight the ongoing focus on clinical progress and financial performance within the…
RXRX
RECURSION PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$3.20
Model IV—
P/IV—
Market implies +35.4%/yr vs model +50.0% · below model
SANA
Sana Biotechnology, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.13
Model IV—
P/IV—
Limited data — see page
SBFM
Sunshine Biopharma Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$1.06
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
SCNI
Scinai Immunotherapeutics Ltd.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$2.44
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$3.53
Model IV—
P/IV—
Limited data — see page
SLS
SELLAS Life Sciences Group, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$11.55
Model IV—
P/IV—
Market implies +114.4%/yr vs model +15.0% · above model
SMMT
Summit Therapeutics Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$17.55
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
SNDX
Syndax Pharmaceuticals Inc
Valuation N/A
Healthcare Risk 67 · High
Price$18.35
Model IV—
P/IV—
Market implies +18.0%/yr vs model +5.4% · above model
SNGX
SOLIGENIX, INC.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.36
Model IV—
P/IV—
Market implies +38.9%/yr vs model +15.0% · above model
SNSE
Sensei Biotherapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$25.96
Model IV—
P/IV—
Limited data — see page
SNTI
Senti Biosciences Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.31
Model IV—
P/IV—
Market implies +96.6%/yr vs model +2.0% · above model
SRRK
Scholar Rock Holding Corp
Valuation N/A
Healthcare Risk 50 · Elevated
Price$55.41
Model IV—
P/IV—
Market implies +71.2%/yr vs model +15.0% · above model
SRTS
Sensus Healthcare, Inc.
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$3.13
Model IV$2.09
P/IV1.48
Premium +50% Return to IV: -33.2%
Market implies +0.8%/yr vs model +2.0% · in line
STRO
SUTRO BIOPHARMA, INC.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$16.86
Model IV—
P/IV—
Market implies -4.2%/yr vs model +13.4% · below model
STTK
Shattuck Labs, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.20
Model IV—
P/IV—
Market implies +108.7%/yr vs model +2.0% · above model
TAK
TAKEDA PHARMACEUTICAL CO LTD
Valuation N/A
Healthcare Risk 37 · Moderate
Price$18.26
Model IV—
P/IV—
Limited data — see page
TARA
Protara Therapeutics, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$3.82
Model IV—
P/IV—
Limited data — see page
TCRT
Alaunos Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$1.51
Model IV—
P/IV—
Market implies +92.7%/yr vs model +2.0% · above model
TCRX
TScan Therapeutics, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$0.32
Model IV—
P/IV—
Market implies +60.9%/yr vs model +2.0% · above model
TELO
Telomir Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.17
Model IV—
P/IV—
Limited data — see page
TEM
Tempus AI, Inc.
Valuation N/A
Technology Risk 36 · Moderate
Price$59.01
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
TGTX
TG THERAPEUTICS, INC.
Fairly valued
Healthcare Risk 47 · Elevated
Price$53.89
Model IV$42.77
P/IV0.89
Premium +26% Return to IV: -20.6%
Market implies -0.8%/yr vs model +50.0% · below model
TIL
Instil Bio, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.38
Model IV—
P/IV—
Limited data — see page
TLSA
Tiziana Life Sciences Ltd
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.96
Model IV—
P/IV—
Limited data — see page
TLSI
TriSalus Life Sciences, Inc.
Deeply overvalued
Healthcare Risk 74 · High
Price$4.78
Model IV$1.56
P/IV2.19
Premium +207% Return to IV: -67.5%
Market implies +11.4%/yr vs model +15.0% · below model
TLX
Telix Pharmaceuticals Ltd
Valuation N/A
Healthcare Risk 35 · Moderate
Price$11.29
Model IV—
P/IV—
Limited data — see page
TNGX
Tango Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$23.89
Model IV—
P/IV—
Market implies +46.9%/yr vs model +13.9% · above model
TOI
Oncology Institute, Inc.
Deeply undervalued
Healthcare Risk 34 · Moderate
Price$6.20
Model IV$10.83
P/IV0.43
Discount 43% Return to IV: +74.6%
Market implies -7.6%/yr vs model +25.5% · below model
TOIIW
Oncology Institute, Inc.
Valuation N/A
Healthcare Risk 57 · Elevated
Price$0.05
Model IV—
P/IV—
Market implies -50.0%/yr vs model +25.5% · below model
TOVX
Theriva Biologics, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.25
Model IV—
P/IV—
Limited data — see page
TPST
Tempest Therapeutics, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$0.81
Model IV—
P/IV—
Limited data — see page
TVGN
Tevogen Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$7.36
Model IV—
P/IV—
Limited data — see page
TVRD
Tvardi Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.87
Model IV—
P/IV—
Market implies -1.3%/yr vs model +15.0% · below model
TYRA
Tyra Biosciences, Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$22.03
Model IV—
P/IV—
Limited data — see page
UNCY
Unicycive Therapeutics, Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$4.71
Model IV—
P/IV—
Market implies +62.3%/yr vs model +15.0% · above model
URGN
UroGen Pharma Ltd.
Valuation N/A
Healthcare Risk 60 · High
Price$42.31
Model IV—
P/IV—
Market implies +37.7%/yr vs model +23.0% · above model
VCYT
VERACYTE, INC.
Deeply overvalued
Healthcare Risk 60 · High
Price$40.87
Model IV$26.84
P/IV1.73
Premium +52% Return to IV: -34.3%
Market implies +21.2%/yr vs model +19.7% · in line
VERU
VERU INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.44
Model IV—
P/IV—
Market implies +10.6%/yr vs model +15.0% · below model
VNRX
VOLITIONRX LTD
Valuation N/A
Healthcare Risk 76 · High
Price$0.31
Model IV—
P/IV—
Market implies -0.8%/yr vs model +50.0% · below model
VOR
Vor Biopharma Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$22.30
Model IV—
P/IV—
Limited data — see page
VRAX
Virax Biolabs Group Ltd
Valuation N/A
Healthcare Risk 33 · Moderate
Price$2.67
Model IV—
P/IV—
Market implies +101.4%/yr vs model +2.0% · above model
VSTM
Verastem, Inc.
Deeply overvalued
Healthcare Risk 62 · High
Price$7.34
Model IV$2.42
P/IV1.79
Premium +204% Return to IV: -67.1%
Market implies +15.7%/yr vs model +50.0% · below model
XBIO
Xenetic Biosciences, Inc.
Deeply overvalued
Healthcare Risk 54 · Elevated
Price$3.90
Model IV$2.04
P/IV1.54
Premium +91% Return to IV: -47.7%
Market implies +7.6%/yr vs model +26.5% · below model
XBIT
XBiotech Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.19
Model IV—
P/IV—
Market implies +31.0%/yr vs model +15.0% · above model
XCUR
EXICURE, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.31
Model IV—
P/IV—
Market implies +28.7%/yr vs model +15.0% · above model
XLO
Xilio Therapeutics, Inc.
Fairly valued
Healthcare Risk 38 · Moderate
Price$8.93
Model IV$8.45
P/IV1.00
Premium +6% Return to IV: -5.3%
Market implies -7.3%/yr vs model +15.0% · below model
XNCR
Xencor Inc
Valuation N/A
Healthcare Risk 42 · Elevated
Price$24.41
Model IV—
P/IV—
Market implies +65.5%/yr vs model +2.0% · above model
ZLAB
Zai Lab Ltd
Valuation N/A
Healthcare Risk 42 · Elevated
Price$24.14
Model IV—
P/IV—
Market implies +37.3%/yr vs model +33.5% · above model
ZNTL
Zentalis Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$3.51
Model IV—
P/IV—
Market implies +22.0%/yr vs model +15.0% · above model
ZYME
Zymeworks Inc.
Deeply overvalued
Healthcare Risk 55 · Elevated
Price$26.24
Model IV$8.98
P/IV2.80
Premium +192% Return to IV: -65.8%
Market implies +9.7%/yr vs model +41.2% · below model